Nickel-Catalyzed C(sp<sup>2</sup>)–H Borylation of Arenes
作者:Arpan Das、Pradip Kumar Hota、Swadhin K. Mandal
DOI:10.1021/acs.organomet.9b00364
日期:2019.9.9
In this study, C(sp2)–Hborylation of arenes was accomplished by a nickel catalyst, resulting in good yield. Alkyl and alkoxy arenes were successfully functionalized, affording C(sp2)–H borylated compounds. It was unraveled that the well-defined abnormal N-heterocyclic carbene based Ni(II) complex breaks into Ni nanoparticles (Ni-NPs), which act as catalytically active species. A series of controlled
ORGANIC ELECTROLUMINESCENCE DEVICE AND DISPLAY DEVICE INCLUDING THE SAME
申请人:Samsung Display Co., Ltd.
公开号:US20200220082A1
公开(公告)日:2020-07-09
Provided are an organic electroluminescence device and a display device including the same. The organic electroluminescence device includes a polycyclic compound represented by Formula 1 in a hole blocking layer and at least one of a first light emitting layer and an electron transport layer, wherein each of Y
1
to Y
5
and Y
11
to Y
15
is independently CH or N, at least four of Y
1
to Y
5
are CH, at least four of Y
11
to Y
15
are CH, and R
1
, R
2
, and R
3
are as disclosed in the description.
Arginine methyltransferase inhibitors and uses thereof
申请人:Epizyme, Inc.
公开号:US09346761B2
公开(公告)日:2016-05-24
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF
申请人:EPIZYME, INC.
公开号:US20160137609A1
公开(公告)日:2016-05-19
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. Formula (I).